Index Every US public charity, on the record

Fund for Ophthalmic Knowledge Inc

New York, New York
EIN 13-4171637Grantmaking public charityLatest return year ending December 2024Its profile as a public charity

Applications

Applications

Schedule I of Form 990 lists the grants made, not how to apply, so this return does not say whether Fund for Ophthalmic Knowledge Inc accepts applications.

From its returns

What it gave

Fund for Ophthalmic Knowledge Inc paid $129,934 in grants in the year ending December 2024.

Grants paid
$129,934
Year ending December 2024
Grants listed
1
To organizations, on that return
Typical grant
$56,128
The median of the grants listed
Year endingGrants paidGrants listed
December 2024$129,9341
December 2023$247,8571

From Schedule I of its Form 990 returns for the years ending December 2023 to December 2024.

Focus and places

What it funds, and where

From the 2 grants listed on its returns for the years ending December 2023 to December 2024. A grant counts toward a focus only when it is linked to the charity that received it: 0 of 2 are.

Focus, by share of linked grant dollars

None of its grants could be linked to a charity with certainty, so no focus is shown.

Where it gave, by number of grants

  • New York2

From Schedule I of its Form 990 returns for the years ending December 2023 to December 2024.

Grants

Recent grants to organizations

The largest grants on its latest returns, as filed. A name links to the charity’s profile when the match is certain.

RecipientYear endingAmountPurpose
MEMORIAL SLOAN KETTERING CANCER CENTERNew York, New YorkDecember 2024$56,128SUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER.
MEMORIAL SLOAN KETTERING CANCER CENTERNew York, New YorkDecember 2023$198,692SUPPORTED RESEARCH ON EYE CANCER PERFORMED AT MSKCC: STUDIES ON CELL FREE DNA IN PLASMA OF RETINOBLASTOMA PATIENTS, STUDIES OF CHOROIDAL INVASION IN RETINOBLASTOMA, STUDIES OF THE USE OF INTRARTERIAL CHEMOTHERAPY IN HISTIOCYTOSIS, STUDIES ON EFFICACY AND TOXICITY OF INTRAVITREAL TOPOTECAN FOR EYE CANCER.

Showing 2 of the 2 grants listed on its returns for the years ending December 2023 to December 2024. From Schedule I of its Form 990 returns for the years ending December 2023 to December 2024.